Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
Tuesday, October 14, 2008 - 13:28
in Health & Medicine
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted. The study is published in the October 18, 2008 issue of the journal AIDS.
Read the whole article on Physorg
More from Physorg
Related
- Efavirenz-based initial therapies associated with better outcomes in HIV-infected adultsTue, 14 Oct 2008, 14:29:00 EDT
- Certain HIV treatment less effective when used with anti-TB therapySun, 3 Aug 2008, 14:35:24 EDT
- Integrating antiretroviral therapy with TB treatment for co-infections reduces mortalityThu, 16 Oct 2008, 11:29:22 EDT
- Highly active antiretroviral therapy of similar benefit for HIV-infected injection drug usersSun, 3 Aug 2008, 14:35:21 EDT
- Study suggests HIV-infected patients should start HAART soonerMon, 27 Oct 2008, 10:15:30 EDT